The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells

Blood

Volumn 92, Issue 2, 1998, Pages 632-638

  Cragg, Louise ^a   Hebbel, Robert P ^a   Miller, Wesley ^a   Solovey, Alex ^a   Selby, Scott ^a   Enright, Helen ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; IRON CHELATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL CARCINOGENESIS; DNA DAMAGE; DRUG EFFECT; HUMAN; HUMAN CELL; IRON OVERLOAD; LIVER CARCINOMA; PRIORITY JOURNAL;

EID: 0032528402     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.2.632     Document Type: Article

References (52)

1. Weinberg ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev 64:65, 1983
2. Ames BN: Endogenous oxidative DNA damage, aging and cancer. Free Radic Res Commun 7:121, 1989
3. Crosby WH: Hemochromatosis: Current concepts and management. Hosp Pract 22:173, 1987
4. Kew MD: Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic liver. Hepatology 11: 1086, 1990
5. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G: Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256, 1985
6. Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, Yaouanq J, Jouanolle H, Campion JP, Launois B, Halliday JW, Powell LW, Brissot P: Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 104:228, 1993
7. Gallerani M, Pulga A, Martinelli L, Ricci A, Bottini E, Dall'Ara G, Faggioli M: Heterozygote beta-thalassemia and neoplastic pathology. Minerva Med 81:175, 1990
8. Stevens RG, Jones DY, Micozzi MS, Taylor PR: Body iron stores and the risk of cancer. N Engl J Med 319:1047, 1988
9. Selby JV, Friedman GD: Epidemiological evidence of an association between body iron stores and risk of cancer. Int J Cancer 41:677, 1988
10. Hann HWL, Kim CY, Lodon WJ, Blumberg BS: Increased serum ferritin in chronic liver disease: A risk factor for primary hepatocarcinoma. Int J Cancer 42:376, 1989
11. Kontoghiorghes GJ: Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol Lett 80:1, 1995
12. Cerutti PA: Prooxidant states and tumor promotion. Science 227:375, 1985
13. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L: Effective chelation of iron in β-thalassemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 295:1509, 1987
14. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA: Comparison of oral iron chelator L1 and desferrioxamine in iron loaded patients. Lancet ii:1275, 1990
15. Agarwal MB, Gupta SS, Viswanathan C, et al: Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependant thalassemia: Indian trial. Br J Haematol 82:460, 1992
16. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918, 1995
17. Kontoghiorghes GK, Jackson MI, Lunec J: In vitro screening of iron chelators using models of free radical damage. Free Rad Res Commun 2:115, 1986
18. Van der Kraaij AMM, Van Eijk HG, Koster JF: Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 80:158, 1989
19. Hubert N, Lescoat G, Sciot R, Moirand R, Jego P, Leroyer P, Brissot P: Regulation of ferritin and transferrin receptor expression by iron in human hepatocyte cultures. J Hepatol 18:301, 1993
20. Azari P, Baugh RF: A simple and rapid procedure for preparation of large quantities of pure ovotransferrin. Arch Biochem Biophys 118:138, 1967
21. Ngo EO, Sun TP, Chang JY, Wang CC, Chi KH, Cheng AL, Nutter LM: Menadione-induced DNA damage in a human tumor cell line. Biochem Pharmacol 42:1961, 1991
22. Kohn KW: DNA as a target in cancer chemotherapy: Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res 16:291, 1979
23. Koch CJ, Giandomenico AR: The alkaline elution technique for measuring DNA single strand breaks: Increased reliability and sensitivity. Anal Biochem 220:58, 1994
24. Dean RT, Nicholson P: The action of nine chelators on iron-dependant radical damage. Free Radic Res 20:83, 1993
25. Kontoghiorghes GJ, Sheppard L: Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorganica Chimica Acta 136:11, 1987
26. Olivieri NF, Koren G, Hermann D, Bentur Y, Chung D, Klein J, St-Louis P, Freedman MH, McClelland RA, Templeton DM: Comparison of oral chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275, 1990
27. Porter JB, Huehns ER, Hider RC: The development of iron chelating drugs, in Hershko C (ed): Iron Chelating Therapy. Baillieres Clin Haematol, 2:257, 1989
28. Mello-Filho A, Meneghini R: Iron is the intracellular metal involved in the production of DNA damage by oxygen radicals. Mutat Res 251:109, 1991
29. Meneghini R: Genotoxicity of active oxygen species in mammalian cells. Mutat Res 195:215, 1988
30. Cochrane CG, Sehraufstätter IV, Hyslop P, Jackson J: Cellular and biochemical events in oxidant injury, in Halliwell B (ed): Oxygen Radicals and Tissue Injury. The Upjohn Company, Bethesda, MD, 1988, pp 49-53
31. Toyokuni S: Iron-induced carcinogenesis: The role of redox regulation. Free Rad Biol Med 20:553, 1996
32. Barry M, Flynn DM, Letsky EA, Rison RA: Long-term chelation therapy in thalassemia major: Effect on iron concentration, liver histology, and clinical progress. Br J Med 1:16, 1974
33. Galleano M, Puntarulo S: Mild iron overload effect on rat liver nuclei. Toxicology 93:125, 1994
34. Zastawny TH, Altman SA, Randers-Eichhorn L, Madurawe R, Lumpkin JA, Dizdaroglu M, Rao G: DNA base modifications and membrane damage in cultured mammalian cells treated with iron ions. Free Rad Biol Med 18:1013, 1995
35. Enright H, Otsuki T, Miller W, Selby S, Hebbel RP: Oxidative damage to DNA in hepatocellular iron overload. Blood 84:604a, 1994 (abstract)
36. Brissot P, Wright TL, Ma WL, Weisiger RA: Efficient clearance of non-transferrin-bound iron by rat liver. J Clin Invest 76:1463, 1985
37. Parkes JG, Templeton DM: Iron transport and subcellular distribution in HepG2 hepatocarcinoma cells. Ann Clin Lab Sci 24:509, 1994
38. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN: Oxidative damage to DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 87:4533, 1990
39. Golconda MS, Ueda N, Shah S: Evidence suggesting that iron and calcium are interrelated in oxidant-induced DNA damage. Kidney Int 44:1228, 1993
40. Miller DM, Spear NH, Aust SD: Effects of deferrioxamine on iron-catalyzed lipid peroxidation. Arch Biochem Biophys 295:240, 1992
41. Hoyes KP, Porter JB: Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Brit J Haematol 85:393, 1993
42. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC: Iron mobilization from hepatocyte monolayer cultures by chelators: The importance of membrane permeability and the iron-binding constant. Blood 72:1497, 1988
43. Motekaitis RJ, Martell AE: Stabilities of the iron(III) delates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorganica Chimica Acta 183:71, 1991
44. Kontoghiorghes GJ: Advances in oral chelation in man. Int J Haematol 55:27, 1992
45. Kontoghiorghes GJ: LI (1,2-dimethyl-3-hydroxypyrid-4-one). Drugs Future 13:413, 1988
46. Kontoghiorghes GJ, Piga A, Hoffbrand AV: Cytotoxic effects of the lipophilic iron chelator omadine. FEBS Lett 204:208, 1986
47. Al-Refaie FN, Sheppard LN, Nortney P, Wonke B, Hoffbrand AV: Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haemtol 89:403, 1995
48. al-Refaie FN, Wonke B, Hoffbrand AV: Deferiprone-associated myelotoxicity. Eur J Haematol 53:298, 1994
49. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF: Arthropathy in thalassemia patients receiving deferiprone. Lancet 343:1471, 1994
50. al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy. A report by the International Study Group on Oral Iron Chelators. Br J Haematol 91:224, 1995
51. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC: Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture. Blood 77:2049, 1991
52. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE: Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydropyridinone iron chelator CP94. Biometals 7:267, 1994